Mark Bach
Chief Tech/Sci/R&D Officer at STRUCTURE THERAPEUTICS INC.
Net worth: 61 712 $ as of 31/03/2024
Profile
Dr. Mark A. Bach, MD, is a Senior Vice President-Clinical Development at Ascendis Pharma A/S. Dr. Bach was previously employed as a Chief Executive Officer by Accumulus Synergy, Inc, a Head-Asia Pacific Medical Sciences by Janssen Pharmaceuticals, Inc., a Vice President-Research & Development by Janssen Pharmaceutical KK, and a VP-Clinical Research Operations Worldwide by Merck & Co., Inc. He received his undergraduate degree from Carleton College, a doctorate degree from The University of Chicago and a doctorate degree from Baylor College of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 15/03/2024 | 4,320 ( 0.00% ) | 61 712 $ | 31/03/2024 |
Mark Bach active positions
| Companies | Position | Start |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Former positions of Mark Bach
| Companies | Position | End |
|---|---|---|
| Accumulus Synergy, Inc | Chief Executive Officer | 01/10/2020 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01/08/2019 |
Janssen Pharmaceutical KK
 Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Chief Tech/Sci/R&D Officer | 01/11/2012 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2010 |
| ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | - |
Training of Mark Bach
| Carleton College | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
| Baylor College of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Private companies | 3 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Janssen Pharmaceutical KK
Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Health Technology |
| Accumulus Synergy, Inc |
- Stock Market
- Insiders
- Mark Bach
